Real-World Experience with Lenvatinib plus Pembrolizumab in Metastatic BRAF Wild-Type Anaplastic Thyroid Carcinoma - PubMed
4 days ago
- #lenvatinib
- #anaplastic thyroid carcinoma
- #pembrolizumab
- Study evaluates lenvatinib plus pembrolizumab (L/P) in metastatic BRAF wild-type anaplastic thyroid carcinoma (BRAFWT-ATC).
- 36 patients with BRAFWT-ATC were treated with first-line L/P outside a clinical trial.
- Primary endpoints included overall response rate (ORR), progression-free survival (PFS), and overall survival (OS).
- Median OS was 7.7 months, and median PFS was 6.2 months.
- Confirmed ORR was 36%, with 9% complete responses and 28% partial responses.
- Common driver mutations included RAS (39%) and NF1 (19%).
- PD-L1 combined positive score was ≥1 in 96% of evaluated specimens.
- Safety profile was consistent with prior studies, with 14% discontinuing pembrolizumab due to immune-related toxicity.
- Results support the clinical efficacy and safety of L/P in BRAFWT-ATC.
- A prospective clinical trial in the U.S. is ongoing (NCT#04171622).